Eikon Therapeutics Presents Seven Abstracts at 2026 ESMO Congress
News related to:Eikon Therapeutics · 2 min read
Eikon Therapeutics, a late-stage clinical biopharmaceutical company based in Millbrae, California, is set to present updates on its clinical pipeline at the 2026 European Society for Medical Oncology (ESMO) Congress in Madrid, Spain, starting on October 23, 2026. The company will share seven abstracts, covering a range of its drug candidates in various stages of development.
The first presentation will focus on the updated data from the TeLuRide-005 Phase 2 trial of EIK1001, a TLR7/8 dual-agonist, in combination with pembrolizumab and histology-appropriate chemotherapy for stage 4 non-small cell lung cancer (NSCLC). This trial includes results from the squamous cohort and pooled results. The presentation is scheduled for Monday, October 26, 2026, from 12:00 to 12:45.
Additionally, Eikon will present the initial data from a Phase 1/2 study of EIK1003, a highly selective non-brain penetrant PARP1 inhibitor, as monotherapy and in combination with chemotherapy in advanced solid tumors. This presentation will be held on Friday, October 23, 2026, from 15:15 to 16:00.
Another presentation will cover initial results from an ongoing Phase 1/2 study of EIK1004, a highly selective CNS-penetrant PARP1 inhibitor, in combination with the novel hormonal agent abiraterone in metastatic prostate cancer. This session is also scheduled for Friday, October 23, 2026, from 15:15 to 16:00.
Eikon will also discuss the preliminary safety, tolerability, and pharmacokinetic data for EIK1005, a Werner (WRN) helicase inhibitor, in a Phase 1/2 study. This presentation will be an ePoster and will take place on Friday, October 23, 2026, from 15:15 to 16:00.
Eikon's initial focus is on oncology, where it is advancing a pipeline of drug candidates targeting areas of high unmet need that could eventually become critical medicines for the treatment of various cancers. The company deploys its technology platform, including its proprietary single molecule tracking system, to develop internally-derived novel therapies, while also leveraging the deep expertise of its management team to in-license promising assets. Eikon’s vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster.
The release notes that Eikon is a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing innovative medicines to address serious unmet medical needs. The company’s product candidates are at various stages of development, with the potential to make significant strides in the treatment of cancers.
The forward-looking statements in the press release include the therapeutic potential, safety, and efficacy of Eikon’s product candidates, the timing for anticipated data readouts, and expected milestones and business objectives for 2026 and beyond, including Eikon’s anticipated presentations at the 2026 ESMO Congress.